Oxo-centered carboxylate-bridged trinuclear complexes deposited on Au(111) by a mass-selective electrospray.

We developed an apparatus for nondestructive in vacuum deposition of mass-selected fragile Cr based metal trinuclear complexes, by modifying a commercial Mass Spectrometer containing an electrospray ionization source. Starting from a solution, this system creates a beam of ionized molecules which is then transferred into an evacuated region where the molecules can be mass selected before deposition. To verify the system efficiency, we deposited sub monolayers of oxo-centered carboxylate-bridged trinuclear complexes (Cr3 and Cr2Ni) on Au(111) surface. By XPS and STM we determined the deposited molecule stoichiometry and the surface coverage. The results show that this apparatus is works well for the in vacuum deposition of molecular nanomagnets and, thanks to its reduced dimensions, it is portable

High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution.

We investigated the efficacy of alpha recombinant human erythropoietin (α-rHuEPO) administered as single agent to 133 patients affected by myelodysplastic syndromes referring to our Institution in the last 10 years. WPSS score was "very low" in 67%, "low" in 19%, "intermediate" in 14%. The starting schedule was: 40,000 IU bi-weekly, with reduction or suspension, when necessary, in responsive patients. According to new IWG criteria, response rate (RR) was 75%, 66%, 59% after 8, 16, 24 weeks, respectively. Comparing "very low" and "low/intermediate" risk, RR was 81% vs. 43% (P < 0.001); 70% vs. 45% (P = 0.040); 63% vs. 42% (P = NS) after 8, 16, 24 weeks. RR was significantly influenced by transfusion dependence (P = 0.039) and basal serum EPO level (P < 0.001). Mean Hb value was 94 ± 11 g/l before therapy; 114 ± 19 after 8 weeks (P < 0.001); 116 ± 18 after 16 weeks (P < 0.001); 114 ± 17 after 24 weeks (P < 0.001). Reduction or suspension of therapy significantly affected Hb level after 4 (P < 0.001) and 8 weeks (P < 0.01). Conversely, restart of full dosage significantly enhanced again Hb level after 4 (P < 0.01) and 8 weeks (P < 0.001). 65% patients are alive (mean survival: 74 weeks). Seventy percent are alive in the "very low risk" group and 38% in "low/intermediate risk" group (P < 0.001). Overall mean follow-up was 69 weeks (range, 8-376): it was 80 weeks in responsive patients (max 376) and 38 weeks in patients who progressively became unresponsive (max 168) (P < 0.01). Median response was 36 weeks, with 33% of patients still responding after one year. Treatment was well tolerated. 0.001). 65% patients are alive (mean survival: 74 weeks). Seventy percent are alive in th

This Land is your Land

Il progetto This Land is your Land ha visto la collaborazione fra il Museo, custode delle memorie del proprio territorio, la Casa delle Culture, punto di raccolta di storie di “altre terre” e i rappresentanti di altri 11 paesi che hanno accolto l’invito, consapevoli delle ricadute positive dell’iniziativa in termini di armonia sociale e sviluppo del dialogo interculturale.Prendendo come spunto di riflessione gli oggetti che il Museo conserva ed espone, dagli strumenti agricoli usati nell’antichità fino alle testimonianze di vita rurale della Raccolta di Villa Sorra, sono emerse esperienze e ricordi personali riconducibili alle diverse realtà di cui ciascuno dei partecipanti custodisce in sé la memoria.Chi sfoglia le pagine dell’agenda o visita la mostra troverà una raccolta di storie condivise che congiungono idealmente Modena e il suo territorio a Congo, Argentina, Albania, Ghana, Marocco, Colombia, Nigeria, Romania, Iran, Turchia, Ucraina in un percorso animato da oggetti, racconti, immagini e filmati di “altre terre” ai quali fanno da contrappunto i materiali delle raccolte del museo

FDG-PET response and clinical prognostic factors predict poor outcome in patients with relapsed or refractory Hodgkin's lymphoma

positive PET predicts poor outcome in relapsed patients with Hodgkin's lymphom

Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H).

Although novel therapies for chronic lymphocytic leukemia have resulted in higher hematologic response rates, the complete eradication of disease rarely occurs. Alemtuzumab (Campath-1H) seems to be extremely effective in this role in pretreated patients. The authors used a molecular semiquantitative polymerase chain reaction (PCR) method to assess the ability of alemtuzumab to induce PCR negativity in eight patients pretreated with fludarabine. IgH rearrangement was coamplified with a housekeeping gene and fluorescent PCR products were analyzed on a DNA automatic sequencer. Each patient was evaluated at diagnosis, after fludarabine, and after Campath-1H. The median interval between the last therapy course with fludarabine and the start of Campath-1H was 14 weeks. Patients received subcutaneous doses up to 10 mg, three times a week, for 12 weeks, with a median dose of 190 mg. After six cycles with fludarabine, only one patient (12.5%) achieved molecular remission, and in three other patients IgH levels decreased by 0.5 to 1 log. At the beginning of Campath-1H administration, all patients were PCR positive, including the one previously found to be negative. At the end of treatment, five patients achieved molecular remission (62.5%), four of them within 1 month after the end of therapy. Seventy-two percent of responses, with 43% of complete responses, were documented on bone marrow smears. A significant reduction of lymph node and spleen diameters was noted in 50% and 33% of patients, respectively. Four patients showed grade 2 skin reaction at the site of the subcutaneous injection and grade 1 or 2 fever. Two patients developed neutropenia (grade 2 and 3) and two hemolytic episodes. Three patients showed cytomegalovirus and one herpes zoster and Epstein-Barr virus reactivation. These results show that Campath-1H represents an efficacious in vivo purging tool with a safe profile